Bonfire of biotech: Forbion aims €470M late-stage fund at bets enabled by market crash

Forbion is back with another late-stage investment fund. Two years after making its first foray into the space, the VC shop has returned with a larger €470 million ($505 million) European growth fund that positions it to capitalize on the collapse in valuations of publicly traded biotechs.